ACAD vs LNTH: fair value comparison
ACADIA Pharmaceuticals Inc. and Lantheus Holdings, Inc. · Updated 2026-09-12
Both currently screen as overvalued on TickrTrends' Forward Fair Value model. Within Healthcare, LNTH currently sits closer to the top of our discount ranking.
| ACAD | LNTH | |
|---|---|---|
| Verdict | Overvalued | Overvalued |
| Last price | $28.89 | $100.88 |
| 12-month range | $21.24–$28.89 | $51.63–$108.96 |
| Sector rank | #113 of 113 Healthcare | #104 of 113 Healthcare |
| Quality grade | A | A |
| Leverage | Low | Low |
| Margin trend | Stable | Contracting |
| Revenue growth | Strong | Modest |
| RSI zone | Neutral | Neutral |
| 50/200-day trend | Uptrend | Mixed |
| DCF cross-check | Overvalued | Fairly Valued |
| 52-week position | The top quarter | The top quarter |
Full single-stock breakdowns: ACAD fair value analysis · LNTH fair value analysis